Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata
Diagnostics to accurately identify sepsis pathogens in hours instead of days.
Learn More About T2 BiosystemsAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
December 10, 2018
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral…
READ MORE
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
December 3, 2018
NEW HAVEN, Conn., Dec. 3, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or…
READ MORE
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion
November 26, 2018
STAMFORD, Conn. and WHIPPANY, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult and pediatric patients with…
READ MORE